NCT01221727View on ClinicalTrials.gov

The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam

PHASE1CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions

Postmenopausal Osteoporosis

Interventions

DRUG

Denosumab

Eighteen (18) subjects will receive 1 fixed dose administration of denosumab.

DRUG

Midazolam

All subjects will receive two oral dose administrations of midazolam.

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY